---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-001790"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:31:55.959677+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Adial Pharmaceuticals director James W. Newman Jr. resigns from Board effective Jan 5, 2026

## Summary
- James W. Newman Jr. resigned as director and member of Audit and Compensation Committees, effective January 5, 2026.
- No disagreement with company operations, policies or practices cited.
- No replacement has been announced.

## SEC filing metadata
- accession: 0001213900-26-001790
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026001790/0001213900-26-001790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026001790/ea027192401-8k_adialpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-001790
- JSON: https://secwatch.observer/filing/0001213900-26-001790.json
- Plain text: https://secwatch.observer/filing/0001213900-26-001790.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.